Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma

Paola Queirolo, Virginia Picasso, Francesco Spagnolo

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Combined BRAF and MEK inhibition out-performed BRAF inhibitor monotherapy in 3 randomized Phase 3 studies for BRAF-mutated metastatic melanoma patients and the combination of BRAF inhibitor dabrafenib with MEK inhibitor trametinib is now an FDA-approved treatment in this setting. Nevertheless, the majority of patients face progressive disease even when treated with the combination. Mechanisms of resistance to BRAF inhibition have been extensively investigated, whilst less is known about the specific mechanisms of resistance to combined therapy.The aim of this paper is to review the efficacy and safety of the combination of BRAF plus MEK inhibitors compared with BRAF inhibitor monotherapy and immunotherapy, as well as to discuss the existing evidence for the mechanisms of resistance to combined therapy and assess future treatment strategies to improve outcome based on data provided by clinical and translational research studies.

Original languageEnglish
Pages (from-to)519-526
Number of pages8
JournalCancer Treatment Reviews
Volume41
Issue number6
DOIs
Publication statusPublished - Jun 1 2015

Fingerprint

Mitogen-Activated Protein Kinase Kinases
Melanoma
Translational Medical Research
Therapeutics
Immunotherapy
Safety

Keywords

  • BRAF
  • Dabrafenib
  • MEK
  • Melanoma
  • Trametinib
  • Vemurafenib

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma. / Queirolo, Paola; Picasso, Virginia; Spagnolo, Francesco.

In: Cancer Treatment Reviews, Vol. 41, No. 6, 01.06.2015, p. 519-526.

Research output: Contribution to journalArticle

Queirolo, Paola ; Picasso, Virginia ; Spagnolo, Francesco. / Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma. In: Cancer Treatment Reviews. 2015 ; Vol. 41, No. 6. pp. 519-526.
@article{4936a2e0f6f44829a6ed0e1d4a7a6422,
title = "Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma",
abstract = "Combined BRAF and MEK inhibition out-performed BRAF inhibitor monotherapy in 3 randomized Phase 3 studies for BRAF-mutated metastatic melanoma patients and the combination of BRAF inhibitor dabrafenib with MEK inhibitor trametinib is now an FDA-approved treatment in this setting. Nevertheless, the majority of patients face progressive disease even when treated with the combination. Mechanisms of resistance to BRAF inhibition have been extensively investigated, whilst less is known about the specific mechanisms of resistance to combined therapy.The aim of this paper is to review the efficacy and safety of the combination of BRAF plus MEK inhibitors compared with BRAF inhibitor monotherapy and immunotherapy, as well as to discuss the existing evidence for the mechanisms of resistance to combined therapy and assess future treatment strategies to improve outcome based on data provided by clinical and translational research studies.",
keywords = "BRAF, Dabrafenib, MEK, Melanoma, Trametinib, Vemurafenib",
author = "Paola Queirolo and Virginia Picasso and Francesco Spagnolo",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.ctrv.2015.04.010",
language = "English",
volume = "41",
pages = "519--526",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma

AU - Queirolo, Paola

AU - Picasso, Virginia

AU - Spagnolo, Francesco

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Combined BRAF and MEK inhibition out-performed BRAF inhibitor monotherapy in 3 randomized Phase 3 studies for BRAF-mutated metastatic melanoma patients and the combination of BRAF inhibitor dabrafenib with MEK inhibitor trametinib is now an FDA-approved treatment in this setting. Nevertheless, the majority of patients face progressive disease even when treated with the combination. Mechanisms of resistance to BRAF inhibition have been extensively investigated, whilst less is known about the specific mechanisms of resistance to combined therapy.The aim of this paper is to review the efficacy and safety of the combination of BRAF plus MEK inhibitors compared with BRAF inhibitor monotherapy and immunotherapy, as well as to discuss the existing evidence for the mechanisms of resistance to combined therapy and assess future treatment strategies to improve outcome based on data provided by clinical and translational research studies.

AB - Combined BRAF and MEK inhibition out-performed BRAF inhibitor monotherapy in 3 randomized Phase 3 studies for BRAF-mutated metastatic melanoma patients and the combination of BRAF inhibitor dabrafenib with MEK inhibitor trametinib is now an FDA-approved treatment in this setting. Nevertheless, the majority of patients face progressive disease even when treated with the combination. Mechanisms of resistance to BRAF inhibition have been extensively investigated, whilst less is known about the specific mechanisms of resistance to combined therapy.The aim of this paper is to review the efficacy and safety of the combination of BRAF plus MEK inhibitors compared with BRAF inhibitor monotherapy and immunotherapy, as well as to discuss the existing evidence for the mechanisms of resistance to combined therapy and assess future treatment strategies to improve outcome based on data provided by clinical and translational research studies.

KW - BRAF

KW - Dabrafenib

KW - MEK

KW - Melanoma

KW - Trametinib

KW - Vemurafenib

UR - http://www.scopus.com/inward/record.url?scp=84937630840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937630840&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2015.04.010

DO - 10.1016/j.ctrv.2015.04.010

M3 - Article

AN - SCOPUS:84937630840

VL - 41

SP - 519

EP - 526

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 6

ER -